GTC Biotherapeutics (fka GTCB)

[St_armands_man]

Let's keep it simple...

Per the valution review below (a third qtr 2007 review), product based biotech firms had M&A revenue multiples of 10.4x.

Hmmm...using only the $75M in revenue figure, it would mean that we'd be looking at $750-$800M. If you use 100M shares outstanding, it takes us to $7.50-$8/share. Are there risks? Sure, but they're being minimized every day. More importantly however, there are some huge opportunities that aren't factored into any of the above.

You can discount it any way you want - it's why I'm in big.

www.scottmaconltd.com/images/publications/SM3Q07%20Healthcare%20Review.pdf